The University of Chicago Header Logo

Connection

Mary Elizabeth Strek to Aged

Back to Details
This is a "connection" page, showing publications Mary Elizabeth Strek has written about Aged.
Mary Elizabeth Strek
Connection Strength
0.987
Aged
  1. The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry. Respir Res. 2024 Jun 21; 25(1):255.
    View in: PubMed
    Score: 0.062
  2. Evaluation of Pulmonary Fibrosis Outcomes by Race and Ethnicity in US Adults. JAMA Netw Open. 2023 03 01; 6(3):e232427.
    View in: PubMed
    Score: 0.056
  3. African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis. Eur Respir J. 2018 06; 51(6).
    View in: PubMed
    Score: 0.041
  4. CT-Pathologic Correlation of Major Types of Pulmonary Fibrosis: Insights for Revisions to Current Guidelines. AJR Am J Roentgenol. 2018 May; 210(5):1034-1041.
    View in: PubMed
    Score: 0.040
  5. CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Disease-Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. AJR Am J Roentgenol. 2018 Feb; 210(2):307-313.
    View in: PubMed
    Score: 0.039
  6. De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. Chest. 2017 09; 152(3):683-685.
    View in: PubMed
    Score: 0.039
  7. CT findings associated with survival in chronic hypersensitivity pneumonitis. Eur Radiol. 2017 Dec; 27(12):5127-5135.
    View in: PubMed
    Score: 0.038
  8. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med. 2016 12; 121:117-122.
    View in: PubMed
    Score: 0.036
  9. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J. 2016 06; 47(6):1767-75.
    View in: PubMed
    Score: 0.035
  10. Predictors of survival in coexistent hypersensitivity pneumonitis with autoimmune features. Respir Med. 2016 05; 114:53-60.
    View in: PubMed
    Score: 0.035
  11. Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther. 2016 Feb; 36:46-52.
    View in: PubMed
    Score: 0.034
  12. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest. 2012 Jul; 142(1):159-167.
    View in: PubMed
    Score: 0.027
  13. Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011 Nov; 140(5):1292-1299.
    View in: PubMed
    Score: 0.025
  14. Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease. Am J Respir Crit Care Med. 2025 Aug; 211(8):1452-1462.
    View in: PubMed
    Score: 0.017
  15. Quantitative CT Scan Analysis in Rheumatoid Arthritis-Related Interstitial Lung Disease. Chest. 2025 May; 167(5):1428-1439.
    View in: PubMed
    Score: 0.016
  16. Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis. Am J Respir Crit Care Med. 2024 Sep 01; 210(5):639-647.
    View in: PubMed
    Score: 0.016
  17. Machine Learning of Plasma Proteomics Classifies Diagnosis of Interstitial Lung Disease. Am J Respir Crit Care Med. 2024 Aug 15; 210(4):444-454.
    View in: PubMed
    Score: 0.016
  18. Molecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts. Am J Respir Crit Care Med. 2024 Aug 15; 210(4):455-464.
    View in: PubMed
    Score: 0.016
  19. Hypersensitivity Pneumonitis on Thin-Section Chest CT Scans: Diagnostic Performance of the ATS/JRS/ALAT versus ACCP Imaging Guidelines. Radiol Cardiothorac Imaging. 2024 Aug; 6(4):e230068.
    View in: PubMed
    Score: 0.016
  20. Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2024 05 01; 209(9):1111-1120.
    View in: PubMed
    Score: 0.015
  21. Deep Learning Classification of Usual Interstitial Pneumonia Predicts Outcomes. Am J Respir Crit Care Med. 2024 05 01; 209(9):1121-1131.
    View in: PubMed
    Score: 0.015
  22. Risk Factors for Hospital Readmission in Patients With Interstitial Lung Disease. Respir Care. 2024 04 22; 69(5):586-594.
    View in: PubMed
    Score: 0.015
  23. A multidimensional classifier to support lung transplant referral in patients with pulmonary fibrosis. J Heart Lung Transplant. 2024 07; 43(7):1174-1182.
    View in: PubMed
    Score: 0.015
  24. Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis. Respir Med. 2023 Oct; 217:107330.
    View in: PubMed
    Score: 0.014
  25. Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia. Chest. 2023 05; 163(5):1156-1165.
    View in: PubMed
    Score: 0.014
  26. High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease. Sci Rep. 2021 11 24; 11(1):22821.
    View in: PubMed
    Score: 0.013
  27. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30; 22(1):257.
    View in: PubMed
    Score: 0.013
  28. Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. Am J Respir Crit Care Med. 2021 07 15; 204(2):197-208.
    View in: PubMed
    Score: 0.013
  29. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med. 2001 Jan; 95(1):1-4.
    View in: PubMed
    Score: 0.012
  30. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
    View in: PubMed
    Score: 0.012
  31. CPAP Adherence, Mortality, and Progression-Free Survival in Interstitial Lung Disease and OSA. Chest. 2020 10; 158(4):1701-1712.
    View in: PubMed
    Score: 0.012
  32. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest. 2020 10; 158(4):1526-1534.
    View in: PubMed
    Score: 0.012
  33. Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2020 03 01; 201(5):564-574.
    View in: PubMed
    Score: 0.011
  34. Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease. Am J Respir Crit Care Med. 2020 01 15; 201(2):250-253.
    View in: PubMed
    Score: 0.011
  35. Diagnostic test interpretation and referral delay in patients with interstitial lung disease. Respir Res. 2019 Nov 12; 20(1):253.
    View in: PubMed
    Score: 0.011
  36. Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients With Idiopathic Pulmonary Fibrosis. Chest. 2019 10; 156(4):715-723.
    View in: PubMed
    Score: 0.011
  37. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases. Ann Am Thorac Soc. 2019 05; 16(5):580-588.
    View in: PubMed
    Score: 0.011
  38. Telomere length and genetic variant associations with interstitial lung disease progression and survival. Eur Respir J. 2019 04; 53(4).
    View in: PubMed
    Score: 0.011
  39. Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation. Am J Respir Crit Care Med. 2019 03 15; 199(6):747-759.
    View in: PubMed
    Score: 0.011
  40. Anti-RNA binding protein positivity in idiopathic interstitial pneumonia. Respir Med. 2019 01; 146:23-27.
    View in: PubMed
    Score: 0.010
  41. Underreporting of Interstitial Lung Abnormalities on Lung Cancer Screening Computed Tomography. Ann Am Thorac Soc. 2018 06; 15(6):764-766.
    View in: PubMed
    Score: 0.010
  42. N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia. BMC Pulm Med. 2018 Feb 08; 18(1):30.
    View in: PubMed
    Score: 0.010
  43. Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort. Chest. 2018 02; 153(2):349-360.
    View in: PubMed
    Score: 0.010
  44. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.009
  45. Interstitial Pneumonia With Autoimmune Features: Value of Histopathology. Arch Pathol Lab Med. 2017 Jul; 141(7):960-969.
    View in: PubMed
    Score: 0.009
  46. Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respir Med. 2017 02; 123:56-62.
    View in: PubMed
    Score: 0.009
  47. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2015 Dec 15; 192(12):1475-82.
    View in: PubMed
    Score: 0.009
  48. A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulm Med. 2015 Nov 21; 15:147.
    View in: PubMed
    Score: 0.009
  49. Thyroid Disease Is Prevalent and Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2015 Sep; 148(3):692-700.
    View in: PubMed
    Score: 0.008
  50. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2083-92.
    View in: PubMed
    Score: 0.008
  51. Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr 18; 31(1):46-54.
    View in: PubMed
    Score: 0.008
  52. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013 May 07; 158(9):641-9.
    View in: PubMed
    Score: 0.007
  53. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2012 Feb; 39(2):344-51.
    View in: PubMed
    Score: 0.006
  54. Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheumatol. 2009 Aug; 15(5):254-5.
    View in: PubMed
    Score: 0.006
  55. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest. 2006 Jan; 129(1):56-66.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.